Compare First Trust Cloud Computing ETF (SKYY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Trust Cloud Computing ETF vs TG Therapeutics Inc — how do they compare? First Trust Cloud Computing ETF trades at $174.89 (market cap $3.47B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 2.4× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold First Trust Cloud Computing ETF for 85 Days and TG Therapeutics Inc for 16 Days on average.
| SKYY | TGTX | |
|---|---|---|
Market Cap | $3.47B | $8.16B |
Volume | 176,159 | 1,735,121 |
52-Week High | $171.01 | $59.06 |
52-Week Low | $104.16 | $26.94 |
Typical Hold Time | 85 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SKYY (First Trust Cloud Computing ETF) trades at $170.14, down 0.37% on the day but near its 52-week high of $169.41. Technical indicators show a bullish trend with strong moving average support and neutral oscillators. The ETF benefits from strong secular trends in cloud computing and AI adoption, with recent news highlighting institutional position adjustments and positive sector momentum.
The outlook remains positive given cloud computing's growth trajectory and AI infrastructure demand. Key risks include sector concentration and market volatility. Analyst sentiment is generally favorable, though valuation metrics are not provided in current data. The ETF's diversified exposure to cloud infrastructure positions it well for continued technology adoption trends.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
